IL-6 拮抗剂与 COVID-19 住院患者死亡率的相关性:一项 Meta 分析
该前瞻性 Meta 分析纳入 27 项随机试验共 10 930 例 COVID-19 住院患者,比较 IL-6 拮抗剂与常规治疗或安慰剂的 28 天全因死亡率。结果显示 IL-6 拮抗剂组死亡率低于对照组(汇总 OR 0.86,95%CI 0.79-0.95;
要点
- IL-6 拮抗剂与 COVID-19 住院患者 28 天全因死亡率降低相关(OR 0.86)。
- 托珠单抗亚组死亡率显著降低(OR 0.83),沙利鲁单抗无显著关联(OR 1.08)。
- 接受皮质类固醇的患者中,托珠单抗仍与死亡率降低相关(OR 0.77)。
研究设计与样本
- 前瞻性 Meta 分析,纳入 27 项随机试验共 10 930 例 COVID-19 住院患者(中位年龄 61 岁,范围 52-68 岁;女性 3560 例,占 33%)。
- 检索电子数据库时间为 2020 年 10 月至 2021 年 1 月,不限制试验状态或语言;从 72 项可能合格的试验中筛选出 27 项(37.5%)符合标准。
- 主要分析为逆方差加权固定效应 Meta 分析,计算 28 天全因死亡率的比值比(OR)。
主要发现
- 绝对死亡风险:IL-6 拮抗剂组为 22%,假设常规治疗或安慰剂组为 25%。
- 在接受皮质类固醇的患者中,托珠单抗与死亡率相关的汇总 OR 为 0.77(95%CI 0.68-0.87),沙利鲁单抗为 0.92(95%CI 0.61-1.38)。
- 进展至有创机械通气或死亡:所有 IL-6 拮抗剂 OR 0.77(95%CI 0.70-0.85),托珠单抗 OR 0.74(95%CI 0.66-0.82),沙利鲁单抗 OR 1.00(95%CI 0.74-1.34)。
关键数值与推荐
- 纳入标准:随机分配 COVID-19 住院患者至 IL-6 拮抗剂组与不使用 IL-6 拮抗剂或其他免疫调节剂(皮质类固醇除外)的对照组。
- 主要结局:随机化后 28 天全因死亡率;次要结局包括进展至有创机械通气或死亡、28 天内继发感染等 9 项。
- 偏倚风险评估使用 Cochrane 偏倚风险评估工具,异质性使用 I2 统计量评估。
临床怎么用
- 对于 COVID-19 住院患者,可考虑使用 IL-6 拮抗剂(尤其是托珠单抗)以降低 28 天全因死亡率。
- 沙利鲁单抗在本分析中未显示与死亡率降低的显著关联,选择药物时需注意差异。
- 接受皮质类固醇的患者中托珠单抗仍与死亡率降低相关,可结合临床情况联合使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. OBJECTIVE: To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. DATA SOURCES: Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts. STUDY SELECTION: Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria. DATA EXTRACTION AND SYNTHESIS: In this prospective meta-analysis, risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I2 statistic. The primary analysis was an inverse variance-weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality. MAIN OUTCOMES AND MEASURES: The primary outcome measure was all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days. RESULTS: A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P = .003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P < .001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P = .52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16). CONCLUSIONS AND RELEVANCE: In this prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality. TRIAL REGISTRATION: PROSPERO Identifier: CRD42021230155.
引用
- Shankar-Hari M, Vale CL, Godolphin PJ, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021. PMID: 34228774. doi:10.1001/jama.2021.11330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。